1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
申请人:G.D. SEARLE & CO.
公开号:EP1077971A1
公开(公告)日:2001-02-28
US6509361B1
申请人:——
公开号:US6509361B1
公开(公告)日:2003-01-21
[EN] 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS<br/>[FR] PYRAZOLES A SUBSTITUTION 1,5-DIARYLE COMME INHIBITEURS DE LA PROTEINE p38 KINASE
申请人:G.D. SEARLE & CO.
公开号:WO1999058523A1
公开(公告)日:1999-11-18
(EN) The present invention contemplates 1,5-diaryl-substituted pyrazole compounds which correspond in structure to Formula (I), or a pharmaceutically-acceptable salt thereof: wherein A is =N- or =CH-; and which inter alia, inhibit the activity of p38 MAP kinase. Also contemplated by the invention are processes for the preparation of the contemplated compounds and for the use of a contemplated compound in treating a mammalian host having a p38 kinase- or TNF-mediated disease.(FR) Cette invention, qui a trait à des composés de pyrazole à substitution 1,5-diaryle, représentés par la formule (I) dans laquelle A représente =N ou =CH-, concerne également un sel de ces composés, acceptable du point de vue pharmaceutique. Ces composés, entre autres effets, inhibent l'activité de la protéine-kinase associée aux membranes, en l'occurrence la protéine p38. Elle porte également sur des procédés de préparation de ces composés ainsi que sur l'utilisation qui est faite de l'un deux pour traiter un mammifère atteint d'une maladie liée à la p38 kinase ou au facteur de nécrose tumorale.
The present invention relates to Pyridinyl pyrazoles of general formula (1) processes for their preparation and their use in medicaments, for the treatment of acute and chronic inflammatory processes, especially for the treatment of COPD.
1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
申请人:Pharmacia Corporation
公开号:US06509361B1
公开(公告)日:2003-01-21
The present invention contemplates 1,5-diaryl-substituted pyrazole compounds that, inter alia, inhibit the activity of p38 MAP kinase. Also contemplated by the invention are processes for the preparation of the contemplated compounds and for the use of a contemplated compound in treating a mammalian host having a p38 kinase- or TNF-mediated disease.